Inventory (NPI). 13 Stable doses of selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenergic reuptake inhibitors (SNRIs), and low-dose trazodone were allowed, but use of other psychotropics was exclusionary. The participants could not have a current major depressive episode or troublesome agitation/aggression, delusions, or hallucinations.
Dosing consisted of a starting dose of 5 mg twice daily of methylphenidate or placebo that, if tolerated, was increased to 10 mg twice daily after 3 days. All study participants and partners received a standardized psychosocial intervention.
The primary outcome measure was an intention-to-treat comparison of the difference in the change from baseline to week 6 on the Apathy Evaluation Scale, 14 with several prespecified and post hoc sensitivity analyses. Secondary outcome measures included the odds ratio for improvement in apathy on the modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC), 15 change in the NPI apathy score, and change in the MiniMental State Examination 16 score for the same time frame. Rates of adverse events were compared between the 2 groups.
The baseline characteristics between the 2 groups were comparable. The participants were in their late 70s on average, the majority were female, and most were white, married, and living in their own home. Participants had high baseline scores on the Apathy Evaluation Scale, revealing meaningful severity of apathy. More than half were taking cognitive enhancers, and although only 17% of subjects had a past diagnosis of depression, 37% were being treated with antidepressants, suggesting that the overlap in symptomatology between apathy and depression might have been confusing to the prescribers. Rosenberg and colleagues 11 point out that SSRI and SNRI antidepressants lack evidence for benefit for this indication and may in fact exacerbate apathy in the elderly.
The vast majority of subjects completed the 6-week study, with 79% of the methylphenidate group and 87% of the placebo group remaining on treatment. Over 80% of participants in both treatment groups remained on the full 20-mg total daily dose. Adverse events and side effects were modest, with trends toward greater anxiety and modest weight loss in the active treatment group.
The primary outcome measure, change in Apathy Evaluation Scale score from baseline to week 6, showed a numerical difference but failed to show statistical significance in favor of methylphenidate. The secondary outcome measures revealed a significant odds ratio of 3.7 for improvement on the modified ADCS-CGIC, with 21% of the active group versus 3% of the placebo group rated as moderately or markedly improved. NPI apathy domain score improvement was significantly in favor of methylphenidate, and the Mini-Mental State Examination score trended toward improvement over placebo.
In summary, finding thoughtful, more effective, and better-tolerated interventions for neuropsychiatric symptoms is a major challenge for investigators and clinicians and must become an urgent priority. The results of the ADMET study suggest that methylphenidate is beneficial in the treatment of apathy in Alzheimer's disease with the intriguing possibility of improving cognition as well. In light of the relatively small sample of this "proof-of-concept" trial and the failure of the primary outcome measure to show a statistical significance, definitive testing of the hypothesis requires a subsequent larger confirmatory trial.
